Loomis, Sayles & Company
AGIO icon

Loomis, Sayles & Company’s Agios Pharmaceuticals AGIO Stock Holding History

Loomis, Sayles & Company’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-417,208
Closed -$13.7M – 726
2024
Q4 		$13.7M Sell
417,208
-195,158
-32% -$9.17M 0.02% 323
2024
Q3 		$27.2M Buy
612,366
+163,503
+36% +$7.43M 0.04% 215
2024
Q2 		$19.4M Buy
+448,863
New +$16.2M 0.03% 261
2021
Q1 		– Sell
-295
Closed -$13K – 835
2020
Q4 		$13K Buy
+295
New +$11.7K ﹤0.01% 675
2018
Q4 		– Sell
-244,675
Closed -$18.9M – 838
2018
Q3 		$18.9M Sell
244,675
-2,649
-1% -$213K 0.04% 231
2018
Q2 		$20.8M Buy
247,324
+1,711
+0.7% +$149K 0.04% 237
2018
Q1 		$20.1M Sell
245,613
-8,113
-3% -$627K 0.04% 244
2017
Q4 		$14.5M Buy
253,726
+42,128
+20% +$2.65M 0.03% 355
2017
Q3 		$14.1M Buy
+211,598
New +$12.7M 0.03% 355

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company's AGIO Position: Q1 2025 in Review

Loomis, Sayles & Company sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 417,208 shares — an estimated $13.7M sold.

Loomis, Sayles & Company first reported a position in AGIO in Q3 2017 and held it in 9 quarters. The position peaked at $27.2M in Q3 2024. 220 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • Loomis, Sayles & Company reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Loomis, Sayles & Company sold 417,208 Agios Pharmaceuticals shares in Q1 2025, an estimated $13.7M.
  • Loomis, Sayles & Company first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • Loomis, Sayles & Company's Agios Pharmaceuticals position peaked at $27.2M in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on Loomis, Sayles & Company's 13F filing for Q1 2025, filed 14 May 2025.